BMS and AZ strengthen their joint diabetes franchise

Sunday 1 July 2012

Bristol-Myers Squibb Company and AstraZeneca Plc are set to strengthen their diabetes franchise through a staged deal in which BMS will acquire Amylin Pharmaceuticals Inc and thereafter exploit Amylin’s portfolio with AstraZeneca

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States